Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands

Emerging Infectious Diseases

Volumn 16, Issue 5, 2010, Pages 816-823

  Rodenburg, Gerwin D ^a   de Greeff, Sabine C ^b   Jansen, Angelique G C S ^a   de Melker, Hester E ^b   Schouls, Leo M ^b   Hak, Eelko ^a,c   Spanjaard, Lodewijk ^d   Sanders, Elisabeth A M ^a   Van der Ende, Arie ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Netherlands Reference Laboratory for Bacterial Meningitis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DETERMINATION; AGED; ARTICLE; BACTERIUM ISOLATE; CHILD; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INCIDENCE; MENINGITIS; NETHERLANDS; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; THERAPY EFFECT; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; MIDDLE AGED; NETHERLANDS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951146390     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1605.091223     Document Type: Article

References (30)

1. Jansen AGSC, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27:2394-401. DOI: 10.1016/j.vaccine.2009.01.127
2. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57:144-8.
3. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:468-72. DOI: 10.1097/INF.0b013e31803df9ca
4. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-51. DOI: 10.1001/jama.294.16.2043
5. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46. DOI: 10.1056/NEJMoa022823
6. Health Council of the Netherlands. Vaccination of infants against pneumococcal infections. The Hague: The Council; 2005.
7. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specifi c pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-40. DOI: 10.1086/313609
8. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-56. DOI: 10.1056/NEJMoa0800836
9. de Carvalho Gomes GH, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill. 2009;14: pii: 19159.
10. van Oosten M, de Greeff SC, Spanjaard L, Schouls LM. Introduction of pneumococcal conjugate vaccine into the Dutch national immunization programme. Euro Surveill. 2006;11:E060608.
11. Episheet RK. Spreadsheets for the analysis of epidemiologic data [cited 2010 Jan 10]. http://www.drugepi.org/links/downloads/episheet.xls
12. van Lier EA, Oomen PJ, Oostenbrug MWM, Zwakhals SLN, Drijfhout IH, de Hoogh PAAM, et al. Vaccinatiegraad Rijksvaccinatie programma Nederland; Verslagjaar 2009. Bilthoven (the Netherlands): National Institute for Public Health and the Environment; 2009 [cited 2010 Jan 10]. http://www.rivm.nl/bibliotheek/rapporten/210021010.pdf
13. Vestrheim DF, Lovoll O, Aaberge IS, Caugant DA, Hoiby EA, Bakke H, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277-81. DOI: 10.1016/j.vaccine.2008.03.087
14. Ruckinger S. van der LM, Reinert RR, von KR, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27:4136-41. DOI: 10.1016/j.vaccine.2009.04.057
15. Aristegui J, Bernaola E, Pocheville I, Garcia C, Arranz L, Duran G, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2007;26:303-10. DOI: 10.1007/s10096-007-0294-4
16. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-82. DOI: 10.1086/524660
17. Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill. 2008;13: pii: 18962.
18. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012-20. DOI: 10.1128/JCM.01454-08
19. Health Protection Agency. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the seven serotypes in Prevenar™: children aged < 2 years in England and Wales by epidemiological year: July-June (2003-to date) [cited 2010 Jan 10]. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1207821645727
20. Health Protection Agency. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes NOT in Prevenar™: children aged < 2 years in England and Wales by epidemiological year: July-June (2003-to date) [cited 2010 Jan 10]. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1207821646480
21. Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell. 2008;32:18-30.
22. Health Protection Agency. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the seven serotypes in Prevenar™: persons aged >5 years in England and Wales by epidemiological year: July-June (2003-to date) [cited 2010 Jan 10]. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1239951968966
23. Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2008;57:480-7. DOI: 10.1099/jmm.0.47690-0
24. Leimkugel J, Adams FA, Gagneux S, Pfluger V, Flierl C, Awine E, et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis. 2005;192:192-9. DOI: 10.1086/431151
25. Brueggemann AB, Spratt BG. Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. J Clin Microbiol. 2003;41:4966-70. DOI: 10.1128/JCM.41.11.4966-4970.2003
26. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298:1772-8. DOI: 10.1001/jama.298.15.1772
27. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159-67. DOI: 10.1001/jama.2009.975
28. Ihekweazu CA, Dance DA, Pebody R, George RC, Smith MD, Waight P, et al. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect. 2008;136:1096-102. DOI: 10.1017/S0950268807009715
29. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197-209 10.1016/j.ijid.2009.05.010. DOI: 10.1016/j.ijid.2009.05.010
30. de Greeff SC, Sanders EA, de Melker HE, van der Ende A, Vermeer PE, Schouls LM. Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specifi c groups at risk [in Dutch]. Ned Tijdschr Geneeskd. 2007;151:1454-7.